Terns Pharmaceuticals, Inc. Capex per Share

Capex per Share of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capex per Share growth rates and interactive chart. Capex per share refers to the total amount of capital expenditures paid in a period divided by the weighted average number of shares outstanding. If a company has capex of $100 million and 10 million shares outstanding, capex per share is $10.


Highlights and Quick Summary

  • Capex per Share for the quarter ending March 31, 2022 was -0.01 (a 21.52% increase compared to previous quarter)
  • Year-over-year quarterly Capex per Share increased by 464.71%
  • Annual Capex per Share for 2021 was -0.01 (a -41.81% decrease from previous year)
  • Annual Capex per Share for 2020 was -0.02 (a -35.38% decrease from previous year)
  • Annual Capex per Share for 2019 was -0.04 (a -Infinity% decrease from previous year)
  • Twelve month Capex per Share ending March 31, 2022 was -0.02 (a 63.7% increase compared to previous quarter)
  • Twelve month trailing Capex per Share increased by 370.21% year-over-year
Trailing Capex per Share for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
-0.02 -0.01 -0.01 -0.0
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capex per Share of Terns Pharmaceuticals, Inc.

Most recent Capex per Shareof TERN including historical data for past 10 years.

Interactive Chart of Capex per Share of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Capex per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -0.01
2021 -0.01 -0.0 -0.0 -0.0 -0.01
2020 -0.0 -0.02 -0.35 -1.99 -0.02
2019 0.0 -0.04
2018 0.0

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.